AbbVie plans to price five series of senior notes

By Lisa Kerner

Charlotte, N.C., May 9 – AbbVie Inc. is in the market with a five-part offering of senior notes, according to a 424B3 filed with the Securities and Exchange Commission.

The offering includes tranches due 2021, 2023, 2026, 2036 and 2046.

BofA Merrill Lynch, Barclays, Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are the joint bookrunners.

Proceeds will be used to fund the cash component of the Stemcentrx Inc. acquisition, to finance share repurchases, to repay the company’s outstanding term loan maturing in November 2016 and for general corporate purposes.

The biopharmaceutical company is based in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.